Search

Your search keyword '"Schreiber, S"' showing total 184 results
Start Over Author "Schreiber, S" Journal gut
184 results on '"Schreiber, S"'

1. Adalimumab for the treatment of fistulas in patients with Crohn's disease

Author

Colombel, J.-F., Schwartz, D.A., Sandborn, W.J., Kamm, M.A., D'Haens, G., Rutgeerts, P., Enns, R., Panaccione, R., Schreiber, S., Li, J., Kent, J.D., Lomax, K.G., and Pollack, P.F.

Subjects
Fistula -- Care and treatment, Fistula -- Research, Crohn's disease -- Care and treatment, Crohn's disease -- Research, Health
Published
2009

3. Bacterial and fungal microbiota in relation to probiotic therapy (VSL#3) in pouchitis

Author

Kuhbacher, T., Ott, S.J., Helwig, U., Mimura, T., Rizzello, F., Kleessen, B., Gionchetti, P., Blaut, M., Campieri, M., Folsch, U.R., Kamm, M.A., and Schreiber, S.

Subjects
Probiotics -- Physiological aspects, Probiotics -- Research, Anastomosis -- Complications and side effects, Surgical anastomosis -- Complications and side effects, Ulcerative colitis -- Care and treatment, Health
Published
2006

4. Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis

Author

Mimura, T., Rizzello, F., Helwig, U., Poggioli, G., Schreiber, S., Talbot, I.C., Nicholls, R.J., Gionchetti, P., Campieri, M., and Kamm, M.A.

Subjects
Health
Abstract

Gut 2004;53:108-114 Background: Ten to 15% of patients with pouchitis experience refractory or recurrent disease. The aim of this study was to evaluate the effectiveness of a single daily high [...]

Published
2004

5. Interferon β-1a in ulcerative colitis: a placebo controlled, randomised, dose escalating study

Author

Nikolaus, S, Rutgeerts, P, Fedorak, R, Steinhart, AH, Wild, GE, Theuer, D, Mohrle, J, and Schreiber, S

Subjects
Interferon beta -- Dosage and administration -- Evaluation, Ulcerative colitis -- Drug therapy -- Patient outcomes, Health, Drug therapy, Evaluation, Patient outcomes, Dosage and administration
Abstract

Background and aims: Administration of interferon (IFN)-β may represent a rational approach to the treatment of ulcerative colitis through its immunomodulatory and anti-inflammatory effects. The present study was performed to [...]

Published
2003

6. Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial. (Inflammatory Bowel Disease)

Author

Probert, C.S.J., Hearing, S.D., Schreiber, S., Kuhbacher, T., Ghosh, S., Arnott, I.D.R., and Forbes, A.

Subjects
Ulcerative colitis -- Drug therapy, Infliximab -- Dosage and administration -- Evaluation, Corticosteroids -- Physiological aspects -- Dosage and administration, Adrenocortical hormones -- Physiological aspects, Health
Abstract

Background: Tumour necrosis factor production is increased in the mucosa of patients with active ulcerative colitis. The benefits of infliximab in Crohn's disease are established. We investigated its efficacy in [...]

Published
2003

7. Activation of signal transducer and activator of transcription (STAT) 1 in human chronic inflammatory bowel disease. (Inflammation and Inflammatory Bowel Disease)

Author

Schreiber, S., Rosenstiel, P., Hampe, J., Nikolaus, S., Groessner, B., Schottelius, A., Kuhbacher, T., Hamling, J., Folsch, U.R., and Seegert, D.

Subjects
Cytokines -- Physiological aspects -- Research, Inflammatory bowel diseases -- Diagnosis -- Research, Cellular signal transduction -- Physiological aspects -- Research, Physiology, Pathological -- Research -- Physiological aspects, Health, Diagnosis, Physiological aspects, Research
Abstract

Background: Increased expression of proinflammatory cytokines, including tumour necrosis factor α, interleukin 6, and interferon γ, as well as activation of proinflammatory signalling molecules such as nuclear factor kappa B, [...]

Published
2002

8. Treatment of Crohn's disease with recombinant human interleukin 10 induces the Proinflammatory cytokine interferon γ. (Inflammation and Inflammatory Bowel Disease)

Author

Tilg, H., Montfrans, C. Van, Den Ende, A. Van, Kaser, A., Deventer, S.J.H. Van, Schreiber, S., Gregor, M., Ludwiczek, O., Rutgeerts, P., Gasche, C., Koningsberger, J.C., Abreu, L., Kuhn, I., Cohard, M, LeBeaut, A., Grint, P., and Weiss, G.

Subjects
Inflammatory bowel diseases -- Care and treatment, Interleukin-10 -- Health aspects, Crohn's disease -- Care and treatment, Health, Care and treatment, Health aspects
Abstract

Background: Interleukin 10 (IL-100) exerts anti-inflammatory actions by counteracting many biological effects of interferon γ (IFN-γ). Aims: To investigate this in humans, we studied the effects of human recombinant IL-10 [...]

Published
2002

9. Low dose balsalazide (1.5 g twice daily) and mesalazine (0.5 g three times daily) maintained remission of ulcerative colitis but high dose balsalazide (3.0 g twice daily) was superior in preventing relapses. (Information and Inflammatory bowel disease)

Author

Kruis, W., Schreiber, S., Theuer, D., Brandes, J.W., Schutz, E., Howaldt, S., Krakamp, B., Hamling, J., Monnikes, H., Koop, I., Stolte, M., Pallant, D., and Ewald, U.

Subjects
Ulcerative colitis -- Drug therapy, Mesalamine -- Evaluation -- Product/service Evaluations, Health, Balsalazide (Medication) -- Evaluation
Abstract

Abstract Background--Balsalazide is a new 5-aminosalicylic acid (5-ASA) containing prodrug. Its efficacy in comparison with standard mesalazine therapy and the optimum dose for maintaining remission of ulcerative colitis are still [...]

Published
2001

30. Safety, tolerance and activity of multiple doses of subcutaneous recombinant human interleukin-10 (rHuIL-10) in patients with mild to moderate active Crohn's disease 11.02

Author

Fedorak, R. N., Gangl, A., Elson, C. O., Gasche, C., Rutgeerts, P., D'Haens, G., Schreiber, S., Wild, G., Hanauer, S. B., Sninsky, C. A., Wilson, J. H. P., Tilg, H., Isaacs, K., Jacyna, M., Colombel, J. F., Desreumaux, P., van Deventer, S. J. H., Wright, J. P., Irvine, E. J., Levine, D. S., Tremaine, W. J., Laschner, B. A., Warner, A. S., McDermott, R., Mayer, L., Koningsberger, J. C., van Gossum, A., Befrits, R., Deusch, K., Targan, S., Gibson, P., Cohard, M., Grint, P., Kilian, A., and LeBeaut, A.

Published
1997

34. A randomised placebo-controlled multicentre trial of intravenous semapimod HCl for moderate to severe Crohn's disease

Author

Dotan, I., Rachmilewitz, D., Schreiber, S., Eliakim, R., Woude, C.J. van der, Kornbluth, A., Buchman, A.L., Bar-Meir, S., Bokemeyer, B., Goldin, E., Maaser, C., Mahadevan, U., Seidler, U., Hoffman, J.C., Homoky, D., Plasse, T., Powers, B., Rutgeerts, P., Hommes, D., Semapimod-CD04 CD05 Investigators, and Gastroenterology & Hepatology

Subjects
Adult, Male, medicine.medical_specialty, Placebo, Severity of Illness Index, Gastroenterology, Inflammatory bowel disease, Drug Administration Schedule, law.invention, Young Adult, chemistry.chemical_compound, Crohn Disease, Double-Blind Method, Gastrointestinal Agents, Randomized controlled trial, law, Internal medicine, Severity of illness, Humans, Medicine, Outpatient clinic, Dosing, Infusions, Intravenous, Semapimod, Crohn's disease, business.industry, Anti-Inflammatory Agents, Non-Steroidal, Hydrazones, Middle Aged, medicine.disease, Surgery, C-Reactive Protein, Treatment Outcome, chemistry, tumor-necrosis-factor inflammatory-bowel-disease monoclonal-antibody ca2 tetravalent guanylhydrazone factor-alpha map kinases suppression inhibition lymphoma infliximab, Female, business, Immunosuppressive Agents
Abstract

Objective Semapimod, a small molecule known to inhibit proinflammatory cytokine activity, was studied to determine the optimal dose necessary to achieve a response in patients with moderate to severe Crohn's disease (CD). Methods A randomised, double-blind, placebo-controlled trial (CD04) was carried out followed by an open-label extension study (CD05). The trial was conducted in international multicentre outpatient clinics and included patients with moderate to severe CD (Crohn's Disease Activity Index (CDAI) 250-400). Placebo was administered for 3 days; 60 mg semapimod intravenously for 1 day with placebo for 2 days; or 60 mg semapimod intravenously for 3 days. Participants who completed CD04 could participate in the open-label extension study, CD05, to receive up to five additional semapimod HCl 60 mg daily doses three times every 6-8 weeks. The main outcome measures were CDAI, Inflammatory Bowel Disease Questionnaire (IBDQ), Crohn's Disease Endoscopic Inflammation Score (CDEIS) and serum C-reactive protein (CRP) concentration. Results 152 patients were randomised in CD04. Responses for 1 and 3 day regimens were similar to placebo for CDAI (p=0.82), IBDQ (p=0.85), CDEIS (p=0.57) and CRP (p=0.40). The only noteworthy treatment-related safety finding was infusion reaction (phlebitis): 7.3, 34.8 and 62.7% for the placebo and 1 and 3 day semapimod treatment groups, respectively (p= 360 mg was associated with decreased CDAI in a limited number of patients.

Published
2010

40. Pregnancy in primary sclerosing cholangitis

Author

Wellge, B. E., primary, Sterneck, M., additional, Teufel, A., additional, Rust, C., additional, Franke, A., additional, Schreiber, S., additional, Berg, T., additional, Gunther, R., additional, Kreisel, W., additional, zu Eulenburg, C., additional, Braun, F., additional, Beuers, U., additional, Galle, P. R., additional, Lohse, A. W., additional, and Schramm, C., additional

Published
2011
Full Text
View/download PDF

41. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial

Author

Reinisch, W., primary, Sandborn, W. J., additional, Hommes, D. W., additional, D'Haens, G., additional, Hanauer, S., additional, Schreiber, S., additional, Panaccione, R., additional, Fedorak, R. N., additional, Tighe, M. B., additional, Huang, B., additional, Kampman, W., additional, Lazar, A., additional, and Thakkar, R., additional

Published
2011
Full Text
View/download PDF

48. No association between the functional CARD4 insertion! deletion polymorphism and inflammatory bowel diseases in the German population.

Author

Franke, A., Ruether, A., Wedemeyer, N., Karisen, T. H., Nebel, A., and Schreiber, S.

Subjects
INFLAMMATORY bowel diseases, CROHN'S disease, ULCERATIVE colitis, COLON diseases, GASTROENTERITIS, PROCTOLOGY
Abstract

The article explains the disassociation between the functional CARD15 insertion or deletion polymorphism and inflammatory bowel diseases in the German population. According to sources, inflammatory bowel diseases are represented by two main subtypes, Crohn's disease (CD) and ulcerative colitis. Based from observations, identification of functional CARD15 variants revealed the important role of impaired barrier integrity and host defence in the pathogenesis of CD and other inflammatory diseases.

Published
2006
Full Text
View/download PDF

49. Slipping the barrier: how variants in CARD 15 could alter permeability of the intestinal wall and population health.

Author

Schreiber, S.

Subjects
*CROHN'S disease, *ILEUM diseases, *INFLAMMATORY bowel diseases, *EPITHELIAL cells, *BACTERIAL cell walls, *INTERLEUKINS
Abstract

The increased intestinal permeability in Crohn's disease is associated with the presence of variants in the CARD15 gene that are regarded as causative for Crohn's disease, suggesting a genetic rather than an environmental background for intestinal Barrier dysfunction in Crohn's disease. [ABSTRACT FROM AUTHOR]

Published
2006
Full Text
View/download PDF

50. Functional analyses of tlpA- and tlpC- homologous chemotaxis sensor mutants of Helicobacter pylori.

Author

Tomoko, M., Ishikawa, N., Inatsu, S., Schreiber, S., Suerbaum, S., Aizawa, S., and Josenhans, C.

Subjects
CELL motility, CHEMOTAXIS, HELICOBACTER pylori
Abstract

Motility and chemotaxis are amongst the most important factors of H. pylori pathogenicity and persistence. We reported previously that H. pylori cells are attracted by urea and that urea plays an important role in the chemotactic motility of H. pylori in viscous media (Infect. Immun. 1998, 66:4832-4837). To investigate in more detail mechanisms of H. pylori chemotaxis, we performed functional analyses of tlpA- and tlpC-homologous chemotaxis sensor mutants of H. pylori. Materials and Methods: The coding sequence of chemoreceptors tlpA and tlpC from different H. pylori strains was amplified by PCR and cloned. A kanamycin cassette was inserted into the coding sequences of tlpA and tlpC to generate mutants by gene disruption. Mutants were analyzed using electron microscopy and various motility assays. For swarming assays, bacterial stabs in 0.3% refined agar in brucella broth (supplemented with 3-10% serum) were performed. For the behavioral analyses of the mutants in several different environments, the tracking software (MoveTr32)was used. Chemotaxis capillary assays were performed in 50mM potassium phosphate buffer (pH7.0) using capillaries containing 10 mM solutions of amino acids as described previously. Results: 1) tlpA and tlpC mutants showed less swarming than the wild type strains. 2) tlpA and tlpC mutants displayed similar behavior compared to the wildtype strains in various liquid media. 3) tlpA and tlpC mutants showed less chemotactic activity towards urea than the wild type. 4) tlpA and tlpC mutants showed the same level of chemotaxis to several amino acids as the wildtype strains. [ABSTRACT FROM AUTHOR]

Published
2002

Catalog

Books, media, physical & digital resources
See catalog results